MiMedx shares spike 37% after reporting double-digit net sales growth in Q1

Shares placental tissues firm MiMedx are up 37% or $1.40 per share to $5.21 in afternoon trading on Wednesday after reporting results earlier in the day that improved on the top and bottom lines. Joseph Capper, CEO, commented, "Our first quarter 2023 results demonstrate an excellent level of focus and execution across our organization, particularly among our commercial team. Our double-digit net sales growth this quarter was driven by robust demand for our new products in the surgical market and an accelerated growth rate in the private physician office setting. Our entire product offering is winning across the care settings we serve, as we work to make our best-in-class placental biologics products available to a large and growing number of patients each day."